# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Debjit Chattopadhyay assumes CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating.
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $88 price target.
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 ...
Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and maintains $105 pric...
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $88 price target.
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from ...
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer-ZUG, Swi...
Oppenheimer analyst Jay Olson maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from...
JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $...